Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence

Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Filomena, Motta, Irene, Pinto, Valeria, Piolatto, Andrea, Ricchi, Paolo, Tartaglione, Immacolata, Origa, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094868/
https://www.ncbi.nlm.nih.gov/pubmed/37048666
http://dx.doi.org/10.3390/jcm12072584
_version_ 1785023944575680512
author Longo, Filomena
Motta, Irene
Pinto, Valeria
Piolatto, Andrea
Ricchi, Paolo
Tartaglione, Immacolata
Origa, Raffaella
author_facet Longo, Filomena
Motta, Irene
Pinto, Valeria
Piolatto, Andrea
Ricchi, Paolo
Tartaglione, Immacolata
Origa, Raffaella
author_sort Longo, Filomena
collection PubMed
description Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness and guide the clinical use of luspatercept in beta-thalassemia, this paper was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies (SITE). After a brief presentation of the core features of luspatercept, a comprehensive set of questions is addressed, covering relevant aspects for the practical management of this new therapeutic option.
format Online
Article
Text
id pubmed-10094868
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100948682023-04-13 Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence Longo, Filomena Motta, Irene Pinto, Valeria Piolatto, Andrea Ricchi, Paolo Tartaglione, Immacolata Origa, Raffaella J Clin Med Opinion Luspatercept has recently been approved for the treatment of beta-thalassemia and its use in clinical practice has been increasing. As it is the first erythroid maturation drug available for this diagnosis, the expertise about its use is still limited. To address this point, and to promote awareness and guide the clinical use of luspatercept in beta-thalassemia, this paper was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies (SITE). After a brief presentation of the core features of luspatercept, a comprehensive set of questions is addressed, covering relevant aspects for the practical management of this new therapeutic option. MDPI 2023-03-29 /pmc/articles/PMC10094868/ /pubmed/37048666 http://dx.doi.org/10.3390/jcm12072584 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Longo, Filomena
Motta, Irene
Pinto, Valeria
Piolatto, Andrea
Ricchi, Paolo
Tartaglione, Immacolata
Origa, Raffaella
Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
title Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
title_full Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
title_fullStr Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
title_full_unstemmed Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
title_short Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
title_sort treating thalassemia patients with luspatercept: an expert opinion based on current evidence
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094868/
https://www.ncbi.nlm.nih.gov/pubmed/37048666
http://dx.doi.org/10.3390/jcm12072584
work_keys_str_mv AT longofilomena treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence
AT mottairene treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence
AT pintovaleria treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence
AT piolattoandrea treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence
AT ricchipaolo treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence
AT tartaglioneimmacolata treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence
AT origaraffaella treatingthalassemiapatientswithluspaterceptanexpertopinionbasedoncurrentevidence

Ejemplares similares